Loading...
•
Mar 30, 2024
Bioventus Q1 2024 Earnings Report
Reported strong first quarter with revenue growth and increased profitability, driven by Pain Treatments and Surgical Solutions, and raised full-year 2024 financial guidance reflecting enhanced revenue growth and strong execution of strategic priorities.
Key Takeaways
Bioventus reported a strong start to the year with an 8.7% increase in worldwide revenue, totaling $129.5 million, and a net loss from continuing operations of $6.0 million, which is an improvement compared to the prior-year period. The company's adjusted EBITDA from continuing operations increased by 33.5% to $22.6 million. Based on this momentum, Bioventus raised its full-year 2024 financial guidance.
Worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period.
On an organic basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions.
Net loss from continuing operations was $6.0 million, compared to a net loss of $100.0 million in the prior-year period.
Adjusted EBITDA from continuing operations totaled $22.6 million, advancing 33.5% compared to the prior year.
Bioventus
Bioventus
Bioventus Revenue by Segment
Bioventus Revenue by Geographic Location
Revenue by Segment
Pain Treatments Revenue
CapyFin.comSurgical Solutions Revenue
CapyFin.comRestorative Therapies Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Bioventus is raising financial guidance for full-year 2024.
Positive Outlook
- Net sales of $535 million to $550 million
- Adjusted EBITDA of $94 million to $99 million
- Non-GAAP EPS of $0.25 to $0.33
Revenue & Expenses
Visualization of income flow from segment revenue to net income